Blog > International Investing > Blog article: Tercica, Inc. (TRCA:NASDAQ) stock doubles on acquisition news
 | Email This Article Email This Article  | 

Tercica, Inc. (TRCA:NASDAQ) stock doubles on acquisition news

Posted June 5, 2008

Baltimore — (TFN): Brisbane-based growth hormone company Tercica, Inc. (TRCA:NASDAQ) will be acquired by French drugmaker Ipsen SA in a stock deal valued at more than $400 million. Ipsen had an option to buy up to 40% of Tercica through to a 2006 deal. It will buy the remaining 44.9 million outstanding shares for $9 each.

That price reflects a 104 percent premium on Wednesday’s closing price of $4.41 per share.

The stock hist $8.90 today before contracting in the afternoon. No volume spike indicating advance buying tipped the company’s hand.

We consider the speculative upside negligible at this point (at least compared to today’s run-up), at less than 10%.

Our momentum play Sequenom, Inc. (Nasdaq:SQNM), which had soared over 20% on news that its nucleic acid technology is able to detect Down’s syndrome, continued to pack on the shekels today, gaining an additional 20%.

Not bad for not working for a day!

****Make sure you sign up for our FREE TFN News Feed for breaking news, special reports and new financial videos. Sign up through your favorite reader here. Or, if you prefer, have the feed delivered to your email.


Related Articles


Posted by J. Christoph Amberger · Filed Under International Investing 

Comments

close Reblog this comment
Powered by Disqus · Learn more
blog comments powered by Disqus